
NST has collaborated with the BSH for the development of guidelines, important for raising standards of care in haematology. This has involved conducting literature searches, providing writing support, and generating documentation for auditing compliance to guidelines since 2013.
Niche has supported the development of over 20 guidelines that have covered the diagnosis and management of diverse haematological indications, including cancer-related venous thrombosis, mantle cell lymphoma, aplastic anaemia, and antiphospholipid syndrome.
"I am pleased by the standard of work delivered by Niche. The writers provide confidence in the written documents they produce and they excel at clear communication. In addition, the contracting process is simple and efficient, communication is open, frequent, and proactive, with any issues getting resolved quickly and efficiently."




Bridging the research-practice gap and raising standards of clinical and patient care, through guidelines, are central to the BSH’s mission. NST has assisted in this, by supporting the development of robust guidelines that reflect the latest research, experience, and clinical expertise. This has involved capturing up-to-date data in literature searches for subsequent abstraction, synthesis, and evaluation. When required, NST has worked closely with authors for writing support and guideline finalisation. Moreover, NST has assisted the BSH in drafting documentation for auditing guideline compliance.
The collaboration between the BSH and NST has lasted over a decade. Key to this is straightforward contracting, seamless meshing of both teams, proactive communication and dissemination of insights. NST’s collective pool of knowledge, alongside familiarity with the BSH’s ethos and processes, has enabled the delivery of high-quality deliverables.
The BSH’s guidelines have incorporated expertise from several sub-specialties, covering the diagnosis and management of various haematological indications. These include cancer-related venous thrombosis, mantle cell lymphoma, aplastic anaemia, sickle cell disease in pregnancy, and antiphospholipid syndrome.
A specialist pharmaceutical company dedicated to HIV medicines and research with an extensive portfolio of prescription.
read moreAstex employs its proprietary Pyramid™ platform to develop innovative therapies targeting challenging or.
read moreThe FRAILOMIC initiative was an international research project aimed at improving the understanding, diagnosis, and.
read moreSynairgen is a UK-based biopharmaceutical company focused on developing innovative treatments for respiratory diseases,.
read moreRecardio is a life science company that focuses on drug-based regenerative therapeutic modalities for treatments of.
read moreCleothena Enterprises Pty Ltd. is a forward-thinking biotechnology company focused on advancing innovative therapeutic.
read moreAdaptimmune specialises in developing novel therapies for the treatment of resistant tumour types.
read moreNabriva Therapeutics was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna..
read moreAssign’s business model relied on bespoke service providers like NST to deliver essential aspects of their business.
read moreBioKinetic Europe was a fully integrated clinical research organisation with its own purpose-designed clinical.
read moreGet our latest news and publications
Sign up to our news letter